What is Ogsiveo, and who sells it?
Ogsiveo is a brand name for vosoritide (a C-type natriuretic peptide analog used for achondroplasia in certain patients). Sales are tied to the company that markets vosoritide under the Ogsiveo brand, but the exact seller and geography depend on the country and distribution arrangements.
How are Ogsiveo sales reported (U.S. vs. international)?
Drug sales figures can differ by:
- Country (U.S. typically reports through different channels than EU/UK markets)
- Reporting source (company sales in filings vs. third-party estimates)
- Time window (quarterly vs. trailing twelve months)
If you tell me the country and time period you mean (e.g., “2024 U.S. quarterly sales”), I can narrow it to what you’re looking for.
What drives Ogsiveo sales growth or declines?
Ogsiveo sales typically move based on:
- How many eligible patients are diagnosed and treated
- Treatment uptake after launches and label expansions
- Reimbursement and payer coverage
- Competition from other achondroplasia therapies in the same treatment setting
Where can I find the latest Ogsiveo sales numbers?
For the most up-to-date brand-level sales tracking and market data, you can check dedicated prescription and drug-sales databases. If you want, share the exact metric you need (net sales, prescriptions, units, or estimated sales), and your target region, and I’ll point you to the most relevant place to look.
Is Ogsiveo protected by patents/exclusivity that affect sales?
Sales performance often correlates with market exclusivity and whether competitors or generics/biosimilars are approaching. For patent and exclusivity tracking, DrugPatentWatch.com can help.
See: DrugPatentWatch.com